Ligand Pharma (LGND) Tops Q2 EPS by 84c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $255.54 +0.38%
Revenue Growth %: +34.1%
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +34.1%
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.42, $0.84 better than the analyst estimate of $0.58. Revenue for the quarter came in at $26.4 million versus the consensus estimate of $24.74 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.85-$5.00, versus the consensus of $4.63. Ligand Pharma sees FY2023 revenue of $124-128 million, versus the consensus of $131 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- MIND Technology (MIND) Misses Q1 EPS by 5c
- Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
